Literature DB >> 17607938

The mammalian target of rapamycin kinase and tumor growth inhibition.

Anne Boulay1, Heidi A Lane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17607938     DOI： 10.1007/978-3-540-31209-3_7

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  14 in total

1.  Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein.

Authors:  Gábor Egervári; Agnes Márk; Melinda Hajdu; Gábor Barna; Zoltán Sápi; Tibor Krenács; László Kopper; Anna Sebestyén
Journal:  Histochem Cell Biol       Date:  2011-03-20       Impact factor: 4.304

2.  Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.

Authors:  Michael Wahl; Susan M Chang; Joanna J Phillips; Annette M Molinaro; Joseph F Costello; Tali Mazor; Sanda Alexandrescu; Janine M Lupo; Sarah J Nelson; Mitchel Berger; Michael Prados; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Daphne Haas-Kogan
Journal:  Cancer       Date:  2017-07-31       Impact factor: 6.860

3.  The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.

Authors:  Irem Dogan Turacli; Ayla Cihan Ozkan; Abdullah Ekmekci
Journal:  Tumour Biol       Date:  2015-06-25

4.  Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Authors:  Jessica L Geiger; Julie E Bauman; Michael K Gibson; William E Gooding; Prakash Varadarajan; Athanasios Kotsakis; Daniel Martin; Jorge Silvio Gutkind; Matthew L Hedberg; Jennifer R Grandis; Athanassios Argiris
Journal:  Head Neck       Date:  2016-05-27       Impact factor: 3.147

Review 5.  Programmed cell death pathways and current antitumor targets.

Authors:  Mei Lan Tan; Jer Ping Ooi; Nawfal Ismail; Ahmed Ismail Hassan Moad; Tengku Sifzizul Tengku Muhammad
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

6.  Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Authors:  Madlaina Breuleux; Matthieu Klopfenstein; Christine Stephan; Cheryl A Doughty; Louise Barys; Saveur-Michel Maira; David Kwiatkowski; Heidi A Lane
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

7.  Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Authors:  Michele Cea; Antonia Cagnetta; Mariateresa Fulciniti; Yu-Tzu Tai; Teru Hideshima; Dharminder Chauhan; Aldo Roccaro; Antonio Sacco; Teresa Calimeri; Francesca Cottini; Jana Jakubikova; Sun-Young Kong; Franco Patrone; Alessio Nencioni; Marco Gobbi; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex.

Authors:  François Pierre Combes; Guillaume Baneyx; Neva Coello; Penny Zhu; William Sallas; Hequn Yin; Jerry Nedelman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-10       Impact factor: 2.745

Review 9.  Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.

Authors:  Sanjiv S Agarwala; Scott Case
Journal:  Oncologist       Date:  2010-03-09

10.  Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.

Authors:  Valentina Masola; Gianluigi Zaza; Simona Granata; Giovanni Gambaro; Maurizio Onisto; Antonio Lupo
Journal:  J Transl Med       Date:  2013-11-20       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.